DOI: 10.36347/sajb.2016.v04i12.004

Pages: 1082-1086

Leukemias are malignant neoplasms of hematopoietic stem cells, characterized by diffuse replacement of the marrow by neoplastic cells. It is one of the leading causes of cancer deaths. The present study was conducted in the Department of Biochemistry, in collaboration with the Department of Medicine (Clinical Haematology unit); Pt. B.D. Sharma, Post Graduate Institute of Medical Sciences, Rohtak. Thirty patients of Chronic Myeloid leukemia after confirmed diagnosis were taken up for study. CML patients were treated by imatinib therapy. Serum hs-CRP was assayed by Enzyme Linked Immunosorbent Assay (ELISA) in newly diagnosed patients and in thirty age and sex matched healthy controls. The test was repeated at first complete remission or at 3 months (whichever is earlier) in CML patients. Group I: Control group- age and sex matched healthy volunteers. Group II: CML patients at the time of diagnosis (before imatinib therapy). Group III: CML patients at first complete remission or at 3 months of imatinib therapy (whichever is earlier). Serum hsCRP levels were significantly increased (p=0.000) in group II and group III (14.75±6.51 mg/L and 9.81±4.64 mg/L respectively) as compared with group I (2.75±1.29 mg/L). In group III hsCRP levels (9.81±4.64 mg/L) were decreased significantly (p=0.001) after imatinib therapy as compared with group II. Our study revealed that hsCRP could be useful marker in determining disease progression or monitor the effectiveness of treatment in leukemic patients as increased levels are seen in CML cases both before and after chemotherapy as compared with their age matched healthy controls.